While we all understand that Covid-19 is a virus, data shows that antibiotics are being utilized at a higher rate and possibly compounding the already growing issue of drug-resistant bacteria. On this front, our fight relies on continued R&D in the pharma space, and research has suffered as a result of the pandemic. This consequence paints a challenging picture in the battle against resistant bacteria that will require a global action plan. The WHO and the ARM Action Fund have provided insightful information and proposed solutions that will affect the healthcare, R&D, and pharmaceutical industries.